Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2018

View Archived Issues

Targeting GPCR prevents pre-eclampsia

Eli Lilly initiates phase I study of its bispecific antibody LY-3415244

Open-source drug discovery yields malaria prevention leads

Amgen presents first-in-human data for AMG-330 in relapsed/refractory AML

IMGN-632 demonstrates initial safety and activity in patients with AML and BPDCN

GMI-1687, a novel inhibitor of E-selectin with promising activity in preclinical models of AML

Icagen and Roche collaborate to develop and commercialize therapy for neurological diseases

Topline results presented from ENCORE-PH phase IIb study in patients with NASH cirrhosis

Phase I data presented for AUTO-3 CAR T-cell therapy targeting CD19 and CD22

Phase II study of elafibranor in primary biliary cholangitis meets primary endpoint

Multidomain antibodies with breadth and potency protect mice from a wide array of influenza strains

Novel thiazolidine free fatty acid FFA2 receptor agonist with improved properties

Novel inhaled PI3Kdelta inhibitor with improved properties for respiratory disease treatment

Phase III EAGLE trial of Imfinzi in head and neck cancer does not meet primary endpoints

FDA approves use of Tecentriq with Avastin and chemotherapy for first-line NSCLC

4D Molecular Therapeutics enters gene therapy collaboration for degenerative retinal diseases

Phase III pediatric ADHD studies with SPN-812 meet primary endpoint

Taizhou Huayuan Medicinal Tech patents brain damage resistance compounds

Prostanoid EP2 and/or EP4 receptor antagonists identified at Idorsia Pharmaceuticals

Phase III study of plinabulin for CIN meets primary endpoint at interim analysis

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine divulge TLR7 agonists

Mitobridge synthesizes new USP30 inhibitors

Biogen exercises option to obtain BIIB-067 from Ionis for ALS

Urate transporter 1 inhibitors patented by Hinova Pharmaceuticals

Low-dose aspirin protects from experimental autoimmune encephalomyelitis

AbbVie stops enrollment in Rova-T SCLC trial on IDMC recommendation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...